Objective To evaluate the indications, techniques and outcome of organ
-preserving tumour enucleation in patients with bilateral testicular g
erm cell tumours (BTGCT) rather than standard bilateral radical orchid
ectomy which results in loss of fertility and a lifelong requirement f
or androgen replacement, Patients and methods In 13 patients with BTGC
T of 6-30 mm in diameter, the tumours were enucleated under cold ischa
emia after inguinal testicular exploration, and biopsies of the tumour
bed and the peripheral parenchyma were taken. Histology of the orchid
ectomy specimen revealed a seminoma in four cases, an embryonal carcin
oma in three, a teratocarcinoma and a mixed-germ cell tumour in two ea
ch, and a mature teratoma in one. Histology of the enucleated tumours
showed a seminoma in seven cases, an embryonal carcinoma in five and a
mature teratoma in one. Six of the 13 patients underwent testicular r
adiation (20 Gy) for carcinoma in situ (CIS) and five patients had adj
uvant local therapy. Six months post-operatively, a testicular biopsy
was taken to determine the success of therapy. Results The median foll
ow-up was 62 months (range 14-163) and the 13 patients are currently f
ree of disease; one patient had local recurrence 9 months after tumour
enucleation but after orchidectomy the patient is free of disease aft
er a follow-up of 156 months. Serum concentrations of luteinizing horm
one and testosterone were within the normal range in all patients and
no androgen substitution was necessary, A testicular biopsy taken 6 mo
nths post-operatively revealed Sertoli cells only in all patients who
had received radiation therapy. Conclusions These results suggest that
organ-sparing surgery in patients with BTGCT represents a new therape
utic approach with endocrinological and psychological advantages. In o
ur experience, enucleation resection of testicular tumours is possible
with certain prerequisites, i.e. the tumour is organ-confined with no
infiltration of the rete testis, multiple biopsies of the tumour bed
and peripheral parenchyma should be taken, any associated CIS treated
by radiation therapy, and patients must be followed closely.